{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:41:36Z","timestamp":1795041696255,"version":"4.10.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interferon-gamma (IFN\u03b3) exerts potent growth inhibitory effects on a wide range of cancer cells through unknown signaling pathways. We pursued complementary screening approaches to characterize the growth inhibition pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed chemical genomics and whole genome targeting CRISPR\/Cas9 screens using patient-derived melanoma lines to uncover essential nodes in the IFN\u03b3-mediated growth inhibition pathway. We used transcriptomic profiling to identify cell death pathways activated upon IFN\u03b3 exposure. Live imaging experiments coupled with apoptosis assays confirmed the involvement of these pathways in IFN\u03b3-mediated cell death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We show that IFN\u03b3 signaling activated ERK. Blocking ERK activation rescued IFN\u03b3-mediated apoptosis in 17 of 23 (~\u200974%) cell lines representing BRAF, NRAS, NF1 mutant, and triple wild type subtypes of cutaneous melanoma. ERK signaling induced a stress response, ultimately leading to apoptosis through the activity of DR5 and NOXA proteins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results provide a new understanding of the IFN\u03b3 growth inhibition pathway, which will be crucial in defining mechanisms of immunotherapy response and resistance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-023-01868-x","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T09:02:05Z","timestamp":1696582925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["ERK mediates interferon gamma-induced melanoma cell death"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-0442","authenticated-orcid":false,"given":"Ameya","family":"Champhekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Saco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Turon Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Maryoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egmidio","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Karin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Damioseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","volume":"38","author":"CS Grasso","year":"2020","unstructured":"Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, et al. Conserved Interferon-\u03b3 signaling drives clinical response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020;38:500\u2013515e3.","journal-title":"Cancer Cell"},{"key":"1868_CR2","doi-asserted-by":"publisher","unstructured":"Castro F, Cardoso AP, Gon\u00e7alves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018 [cited 2018 Oct 31];9. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2018.00847\/full.","DOI":"10.3389\/fimmu.2018.00847\/full"},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22:158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"1868_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258\u201367.","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"1868_CR5","doi-asserted-by":"crossref","unstructured":"Alspach E, Lussier DM, Schreiber RD. Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic Cancer immunity. Cold Spring Harb Perspect Biol. 2018;a028480.","DOI":"10.1101\/cshperspect.a028480"},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1182\/blood.V93.10.3309.410k04_3309_3316","volume":"93","author":"C Dai","year":"1999","unstructured":"Dai C, Krantz SB. Interferon \u03b3 induces Upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood. 1999;93:3309\u201316.","journal-title":"Blood"},{"key":"1868_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1126\/science.272.5262.719","volume":"272","author":"YE Chin","year":"1996","unstructured":"Chin YE, Kitagawa M, Su W-CS, You Z-H, Iwamoto Y, Fu X-Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1\/CIP1 mediated by STAT1. Science. 1996;272:719\u201322.","journal-title":"Science"},{"key":"1868_CR8","first-page":"2832","volume":"58","author":"X Xu","year":"1998","unstructured":"Xu X, Fu X-Y, Plate J, Chong AS-F. IFN-\u03b3 induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for Up-Regulation of Fas and FasL expression. Cancer Res. 1998;58:2832\u20137.","journal-title":"Cancer Res"},{"key":"1868_CR9","first-page":"4115","volume":"26","author":"Y Miura","year":"2006","unstructured":"Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, et al. TRAIL expression Up-regulated by Interferon-\u03b3 via phosphorylation of STAT1 induces Myeloma Cell Death. Anticancer Res. 2006;26:4115\u201324.","journal-title":"Anticancer Res"},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1046\/j.0022-202X.2004.22237.x","volume":"122","author":"A Bosserhoff","year":"2004","unstructured":"Bosserhoff A, Kortylewski M, Komyod W, Kauffmann M-E, Heinrich PC, Behrmann I. Interferon-\u03b3-Mediated growth regulation of Melanoma cells: involvement of STAT1-Dependent and STAT1-Independent signals. J Invest Dermatol. 2004;122:414\u201322.","journal-title":"J Invest Dermatol"},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1128\/MCB.05445-11","volume":"31","author":"RJ Thapa","year":"2011","unstructured":"Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, et al. NF-\u03baB protects cells from Gamma Interferon-Induced RIP1-Dependent necroptosis. Mol Cell Biol. 2011;31:2934\u201346.","journal-title":"Mol Cell Biol"},{"key":"1868_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/jlb.62.6.859","volume":"62","author":"BK English","year":"1997","unstructured":"English BK, Orlicek SL, Mei Z, Meals EA. Bacterial LPS and IFN-\u03b3 trigger the tyrosine phosphorylation of vav in macrophages: evidence for involvement of the hck tyrosine kinase. J Leukoc Biol. 1997;62:859\u201364.","journal-title":"J Leukoc Biol"},{"key":"1868_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1074\/jbc.M004885200","volume":"276","author":"J Hu","year":"2001","unstructured":"Hu J, Roy SK, Shapiro PS, Rodig SR, Reddy SPM, Platanias LC, et al. ERK1 and ERK2 activate CCAAAT\/Enhancer-binding Protein-\u03b2-dependent gene transcription in response to Interferon-\u03b3. J Biol Chem. 2001;276:287\u201397.","journal-title":"J Biol Chem"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S1471-4906(01)02118-4","volume":"23","author":"CV Ramana","year":"2002","unstructured":"Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-\u03b3-dependent signaling. Trends Immunol. 2002;23:96\u2013101.","journal-title":"Trends Immunol"},{"key":"1868_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391.","journal-title":"Nat Biotechnol"},{"key":"1868_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828\u201363.","journal-title":"Nat Protoc"},{"key":"1868_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7:188\u2013201.","journal-title":"Cancer Discov"},{"key":"1868_CR19","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","volume":"16","author":"UA Germann","year":"2017","unstructured":"Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, et al. Targeting the MAPK signaling pathway in Cancer: promising preclinical activity with the Novel Selective ERK1\/2 inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017;16:2351\u201363.","journal-title":"Mol Cancer Ther"},{"key":"1868_CR20","first-page":"1681","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic Classif Cutan Melanoma Cell. 2015;161:1681\u201396.","journal-title":"Genomic Classif Cutan Melanoma Cell"},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"23512","DOI":"10.1074\/jbc.271.38.23512","volume":"271","author":"Y Ueda","year":"1996","unstructured":"Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C \u03b4 activates the MEK-ERK Pathway in a Manner Independent of ras and dependent on Raf*. J Biol Chem. 1996;271:23512\u20139.","journal-title":"J Biol Chem"},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.tcb.2006.09.008","volume":"16","author":"G Posern","year":"2006","unstructured":"Posern G, Treisman R. Actin\u2019 together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol. 2006;16:588\u201396.","journal-title":"Trends Cell Biol"},{"key":"1868_CR23","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374\u201395.","journal-title":"EMBO Rep"},{"key":"1868_CR24","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1074\/jbc.M509868200","volume":"281","author":"J Li","year":"2006","unstructured":"Li J, Lee B, Lee AS. Endoplasmic reticulum stress-induced apoptosis: Multiple pathways and activation of p53-up-regulated modulator of apoptosis (puma) and noxa BY p53*. J Biol Chem. 2006;281:7260\u201370.","journal-title":"J Biol Chem"},{"key":"1868_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.molcel.2018.06.038","volume":"71","author":"T-K Chang","year":"2018","unstructured":"Chang T-K, Lawrence DA, Lu M, Tan J, Harnoss JM, Marsters SA, et al. Coordination between two branches of the unfolded protein response determines apoptotic cell fate. Mol Cell. 2018;71:629\u2013636e5.","journal-title":"Mol Cell"},{"key":"1868_CR26","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41418-018-0155-y","volume":"25","author":"M Lam","year":"2018","unstructured":"Lam M, Lawrence DA, Ashkenazi A, Walter P. Confirming a critical role for death receptor 5 and caspase-8 in apoptosis induction by endoplasmic reticulum stress. Cell Death Differ. 2018;25:1530\u20131.","journal-title":"Cell Death Differ"},{"key":"1868_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1254312","volume":"345","author":"M Lu","year":"2014","unstructured":"Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, et al. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science. 2014;345:98\u2013101.","journal-title":"Science"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tibs.2022.06.007","volume":"47","author":"M Fischer","year":"2022","unstructured":"Fischer M, Schade AE, Branigan TB, M\u00fcller GA, DeCaprio JA. Coordinating gene expression during the cell cycle. Trends Biochem Sci. 2022;47:1009\u201322.","journal-title":"Trends Biochem Sci"},{"key":"1868_CR29","doi-asserted-by":"crossref","unstructured":"Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. Ron D, editor. eLife. 2013;2:e00498.","DOI":"10.7554\/eLife.00498"},{"key":"1868_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-017-0164-7","volume":"9","author":"A Cano-Gonz\u00e1lez","year":"2018","unstructured":"Cano-Gonz\u00e1lez A, Mauro-Lizcano M, Iglesias-Serret D, Gil J, L\u00f3pez-Rivas A. Involvement of both caspase-8 and noxa-activated pathways in endoplasmic reticulum stress-induced apoptosis in triple-negative breast tumor cells. Cell Death Dis. 2018;9:1\u201316.","journal-title":"Cell Death Dis"},{"key":"1868_CR31","doi-asserted-by":"crossref","unstructured":"Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk SP. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. Macleod KF, Murphy ME, editors. eLife. 2020;9:e54954.","DOI":"10.7554\/eLife.54954"},{"key":"1868_CR32","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15440","volume":"8","author":"A Sucker","year":"2017","unstructured":"Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:1\u201315.","journal-title":"Nat Commun"},{"key":"1868_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-\u03b3 pathway genes in Tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy. Cell. 2016;167:397\u2013404e9.","journal-title":"Cell"},{"key":"1868_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 blockade in Melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"key":"1868_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/2326-6066.CIR-22-0056","volume":"11","author":"T Han","year":"2023","unstructured":"Han T, Wang X, Shi S, Zhang W, Wang J, Wu Q, et al. Cancer Cell Resistance to IFN\u03b3 can occur via enhanced double-strand break repair pathway activity. Cancer Immunol Res. 2023;11:381\u201398.","journal-title":"Cancer Immunol Res"},{"key":"1868_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41467-020-14290-4","volume":"11","author":"JB Williams","year":"2020","unstructured":"Williams JB, Li S, Higgs EF, Cabanov A, Wang X, Huang H, et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-\u03b3-signaling mutant cancer cells. Nat Commun. 2020;11:602.","journal-title":"Nat Commun"},{"key":"1868_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.celrep.2015.07.011","volume":"12","author":"C Fr\u00e9min","year":"2015","unstructured":"Fr\u00e9min C, Saba-El-Leil MK, L\u00e9vesque K, Ang S-L, Meloche S. Functional redundancy of ERK1 and ERK2 MAP kinases during development. Cell Rep. 2015;12:913\u201321.","journal-title":"Cell Rep"},{"key":"1868_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1541-7786.MCR-18-0327","volume":"17","author":"GP Leung","year":"2019","unstructured":"Leung GP, Feng T, Sigoillot FD, Geyer FC, Shirley MD, Ruddy DA, et al. Hyperactivation of MAPK signaling is deleterious to RAS\/RAF-mutant Melanoma. Mol Cancer Res. 2019;17:199\u2013211.","journal-title":"Mol Cancer Res"},{"key":"1868_CR40","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.molcel.2015.06.020","volume":"59","author":"S Shin","year":"2015","unstructured":"Shin S, Buel GR, Wolgamott L, Plas DR, Asara JM, Blenis J, et al. ERK2 mediates metabolic stress response to regulate cell fate. Mol Cell. 2015;59:382\u201398.","journal-title":"Mol Cell"},{"key":"1868_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2337\/diabetes.54.2.402","volume":"54","author":"F Bost","year":"2005","unstructured":"Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M, et al. The Extracellular Signal\u2013Regulated kinase isoform ERK1 is specifically required for in Vitro and in vivo adipogenesis. Diabetes. 2005;54:402\u201311.","journal-title":"Diabetes"},{"key":"1868_CR42","doi-asserted-by":"publisher","first-page":"djv435","DOI":"10.1093\/jnci\/djv435","volume":"108","author":"F Sabbatino","year":"2016","unstructured":"Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, et al. Antitumor activity of BRAF inhibitor and IFN\u03b1 combination in BRAF-Mutant Melanoma. JNCI J Natl Cancer Inst. 2016;108:djv435.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1868_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1868_CR44","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-021-00967-z","volume":"53","author":"T Ito","year":"2021","unstructured":"Ito T, Young MJ, Li R, Jain S, Wernitznig A, Krill-Burger JM, et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat Genet. 2021;53:1664\u201372.","journal-title":"Nat Genet"},{"key":"1868_CR45","doi-asserted-by":"crossref","unstructured":"Gutierrez-Prat N, Zuberer HL, Mangano L, Karimaddini Z, Wolf L, Tyanova S et al. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Life Sci Alliance. 2022 [cited 2022 Jun 19];5. Available from: https:\/\/www.life-science-alliance.org\/content\/5\/9\/e202101235.","DOI":"10.26508\/lsa.202101235"},{"key":"1868_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/pcmr.12919","volume":"34","author":"E Christodoulou","year":"2021","unstructured":"Christodoulou E, Rashid M, Pacini C, Droop A, Robertson H, van Groningen T, et al. Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma. Pigment Cell Melanoma Res. 2021;34:122\u201331.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1868_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","volume":"8","author":"A Hong","year":"2018","unstructured":"Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, et al. Exploiting drug addiction mechanisms to select against MAPKi-Resistant melanoma. Cancer Discov. 2018;8:74\u201393.","journal-title":"Cancer Discov"},{"key":"1868_CR48","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature24037","volume":"550","author":"X Kong","year":"2017","unstructured":"Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song J-Y, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550:270\u20134.","journal-title":"Nature"},{"key":"1868_CR49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","volume":"1","author":"R Thibaut","year":"2020","unstructured":"Thibaut R, Bost P, Milo I, Cazaux M, Lema\u00eetre F, Garcia Z, et al. Bystander IFN-\u03b3 activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat Cancer. 2020;1:302\u201314.","journal-title":"Nat Cancer"},{"key":"1868_CR50","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s43018-020-0036-4","volume":"1","author":"ME Hoekstra","year":"2020","unstructured":"Hoekstra ME, Bornes L, Dijkgraaf FE, Philips D, Pardieck IN, Toebes M, et al. Long-distance modulation of bystander tumor cells by CD8 + T-cell-secreted IFN-\u03b3. Nat Cancer. 2020;1:291\u2013301.","journal-title":"Nat Cancer"}],"updated-by":[{"DOI":"10.1186\/s12943-024-01949-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01868-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T09:04:48Z","timestamp":1707383088000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01868-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01868-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12943-024-01949-5","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-024-01949-5","URL":"https:\/\/doi.org\/10.1186\/s12943-024-01949-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.C. and A.R. report a pending patent covering the use of ERK activators for cancer immunotherapy. K.M.C. has received consulting fees from PACT Pharma, Tango Therapeutics, Flagship Labs 81 LLC, the Rare Cancer Research Foundation, and Geneoscopy LLC, and is a shareholder in Geneoscopy LLC. G.A-R. has received honoraria from consulting with Arcus Biosciences. A.R. has received honoraria from consulting with Amgen, Bristol-Myers Squibb, Merck, Novartis, is or has been a member of the scientific advisory board and holds stock in Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, Inspirna, Larkspur, Lutris, MapKure, Merus, Pluto, Synthekine and Tango, has received research funding from Agilent and from Bristol-Myers Squibb through Stand Up to Cancer (SU2C), and patent royalties from Arsenal Bio. RD has received consulting fees from Amgen, Panorama Medicine and is co-founder of Forcyte Biotechnologies and Pharma15 and Enspire Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}